UBS raised the firm’s price target on Xylem (XYL) to $168 from $164 and keeps a Buy rating on the shares. Xylem’s Q2 results indicate the company is still flowing through relatively smooth waters, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL: